title: High-risk and multiple human papillomavirus infections among married women in Can Tho, Viet Nam.
abstract: BACKGROUND
  The two currently licensed human papillomavirus (HPV) vaccines are highly efficacious in preventing cervical pre-cancers related to HPV 6, 11, 16 and 18. Before implementing a large-scale HPV vaccine campaign in Viet Nam, information about the prevalence of infection with the HPV vaccine types is required. This study was done in Can Tho, the province with the highest prevalence of cervical cancer in the south of Viet Nam, to explore the distribution of other high-risk types of HPV among married women in this province.
  
  
  METHODS
  The study employed a cross-sectional design with multistage sampling. A total of 1000 participants were randomly selected, interviewed and given gynaecological examinations. HPV infection status and HPV genotyping test were completed for all participants.
  
  
  RESULTS
  A broad spectrum of HPV types was reported in this study. The prevalence of cases infected with HPV 16 and/or 18 was 7%; the prevalence of cases infected with other high-risk HPV types was 6%. The highest prevalence for single and multiple infections, as well as for high-risk infections, was reported for the youngest age group (less than 30 years).
  
  
  CONCLUSIONS
  While it is relevant to implement an HPV vaccine campaign in Viet Nam due to the high prevalence of infection with HPV 16 and/or 18, it is important to note that one can be infected with multiple types of HPV. Vaccination does not protect against all types of high-risk HPV. Future vaccine campaigns should openly disclose this information to women receiving vaccines.
authors.affiliation: Head, Department of Epidemiology, Ha Noi School of Public Health, Ha Noi, Viet Nam .
authors.forename: Lan Thi Hoang
authors.initials: LT
authors.lastname: Vu
references.citation: Asian Pac J Cancer Prev. 2012;13(1):37-40
references.pmid: 22502703
references.citation: Bull World Health Organ. 2001;79(10):954-62
references.pmid: 11693978
references.citation: Ann Intern Med. 2012 Jun 19;156(12):880-91, W312
references.pmid: 22711081
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):45-52
references.pmid: 11205488
references.citation: Lancet Oncol. 2005 May;6(5):271-8
references.pmid: 15863374
references.citation: Br J Cancer. 2003 Jan 13;88(1):63-73
references.pmid: 12556961
references.citation: JAMA. 2007 Feb 28;297(8):813-9
references.pmid: 17327523
references.citation: Vaccine. 2008 Jul 29;26(32):4015-24
references.pmid: 18602731
references.citation: Asia Pac J Public Health. 2012 Mar;24(2):385-90
references.pmid: 21362673
references.citation: Int J Cancer. 2004 Jul 10;110(5):775-7
references.pmid: 15146569
references.citation: Vaccine. 2008 Aug 19;26 Suppl 10:K1-16
references.pmid: 18847553
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1129-36
references.pmid: 11700260
references.citation: Int J Cancer. 2003 Mar 20;104(2):213-20
references.pmid: 12569577
references.citation: Obstet Gynecol. 1992 Mar;79(3):328-37
references.pmid: 1310805
references.citation: Asian Pac J Cancer Prev. 2011;12(2):561-6
references.pmid: 21545230
references.citation: BMJ. 2002 Sep 14;325(7364):572
references.pmid: 12228133